Sarah Bush Lincoln to Use Biovista’s Project Prodigy Artificial Intelligence Engine to Identify and Validate New Therapeutic Options for Further Research

January 19, 2017Press Releases

Charlottesville, VA (PRWEB) January 19, 2017 Sarah Bush Lincoln (SBL), a hospital and health care organization that is home to more than 300,000 provider office visits per year, and Biovista announced today that they will be working together to validate novel therapeutic options generated in the real-world practice of a hospital and health center, using … Read More

Customer experience in the life science reagent market: the role of content

January 16, 2017Vizit Blog

Customer experience is emerging as a valuable and defensible differentiator for vendors in the life science reagent market. In the past, product quality and price were the two criteria that strongly determined purchase decisions. But this is no longer the case. Many vendors are already competing on price  and at the same time reacting to the increasing pressure … Read More

Biovista announces strong preclinical results for two drugs targeting Niemann-Pick Disease Type A

January 12, 2017Press Releases

CHARLOTTESVILLE, Va. – Jan. 12, 2017 – Biovista Inc. today announced that two drugs targeting Niemann-Pick Disease Type A (NPA), have shown strong positive results in the Acid Sphingomyelinase ASM knock-out (ASMKO) mouse model. Both repositioning candidates (BVA-901A and BVA-901B) tested by the laboratory of Dr. M.D. Ledesma at the Madrid Center for Molecular Biology … Read More